Suzhou Basecare Medical Corp. Ltd. Class H Statistics
Want to see HK:2170 full AI Analyst Report?
Suzhou Basecare Medical Corp. Ltd. Class H (2170) Stock Statistics & Valuation Metrics
Total Valuation
Suzhou Basecare Medical Corp. Ltd. Class H has a market cap or net worth of HKD 374.73M. The enterprise value is HKD 345.20M.
- Market Cap
- HKD 374.73M
- Enterprise Value
- HKD 345.20M
Share Statistics
Suzhou Basecare Medical Corp. Ltd. Class H has 82,713,840 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 82,713,840
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Suzhou Basecare Medical Corp. Ltd. Class H’s return on equity (ROE) is -0.24 and return on invested capital (ROIC) is -16.33%.
- Return on Equity (ROE)
- -0.24
- Return on Assets (ROA)
- -0.15
- Return on Invested Capital (ROIC)
- -16.33%
- Return on Capital Employed (ROCE)
- -0.17
- Revenue Per Employee
- 601.21K
- Profits Per Employee
- -575.91K
- Employee Count
- 388
- Asset Turnover
- 0.16
- Inventory Turnover
- 0.91
Valuation Ratios
The current PE Ratio of Suzhou Basecare Medical Corp. Ltd. Class H is -1.82. Suzhou Basecare Medical Corp. Ltd. Class H’s PEG ratio is -0.06.
- PE Ratio
- -1.82
- PS Ratio
- 1.22
- PB Ratio
- 0.37
- Price to FCF
- -2.40
- Price to Operating Cash Flow
- -3.26
- PEG Ratio
- -0.06
Income Statement
In the last 12 months, Suzhou Basecare Medical Corp. Ltd. Class H had revenue of 233.27M and earned -223.46M in profits. Earnings per share was -0.82.
- Revenue
- 233.27M
- Gross Profit
- 123.61M
- Operating Income
- -214.08M
- Pretax Income
- -227.19M
- Net Income
- -223.46M
- EBITDA
- -162.43M
- Earnings Per Share (EPS)
- -0.82
Cash Flow
In the last 12 months, operating cash flow was -97.88M and capital expenditures -34.63M, giving a free cash flow of -132.51M billion.
- Operating Cash Flow
- -97.88M
- Free Cash Flow
- -132.51M
- Free Cash Flow per Share
- -0.48
Dividends & Yields
Suzhou Basecare Medical Corp. Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -41.73%
- Earnings Yield
- -54.71%
Stock Price Statistics
- Beta
- 0.55
- 52-Week Price Change
- -44.08%
- 50-Day Moving Average
- 1.32
- 200-Day Moving Average
- 1.57
- Relative Strength Index (RSI)
- 56.43
- Average Volume (3m)
- 61.63K
Important Dates
Suzhou Basecare Medical Corp. Ltd. Class H upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 28, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Suzhou Basecare Medical Corp. Ltd. Class H as a current ratio of 3.98, with Debt / Equity ratio of 36.74%
- Current Ratio
- 3.98
- Quick Ratio
- 3.34
- Debt to Market Cap
- 0.75
- Net Debt to EBITDA
- 0.47
- Interest Coverage Ratio
- -16.32
Taxes
In the past 12 months, Suzhou Basecare Medical Corp. Ltd. Class H has paid 3.74M in taxes.
- Income Tax
- 3.74M
- Effective Tax Rate
- -0.02
Enterprise Valuation
Suzhou Basecare Medical Corp. Ltd. Class H EV to EBITDA ratio is -2.86, with an EV/FCF ratio of -2.16.
- EV to Sales
- 1.10
- EV to EBITDA
- -2.86
- EV to Free Cash Flow
- -2.16
- EV to Operating Cash Flow
- -2.92
Balance Sheet
Suzhou Basecare Medical Corp. Ltd. Class H has HKD 378.43M in cash and marketable securities with HKD 342.35M in debt, giving a net cash position of HKD 36.08M billion.
- Cash & Marketable Securities
- HKD 378.43M
- Total Debt
- HKD 342.35M
- Net Cash
- HKD 36.08M
- Net Cash Per Share
- HKD 0.44
- Tangible Book Value Per Share
- HKD 2.32
Margins
Gross margin is 53.61%, with operating margin of -64.08%, and net profit margin of -66.76%.
- Gross Margin
- 53.61%
- Operating Margin
- -64.08%
- Pretax Margin
- -68.43%
- Net Profit Margin
- -66.76%
- EBITDA Margin
- -38.41%
- EBIT Margin
- -55.64%
Analyst Forecast
The average price target for Suzhou Basecare Medical Corp. Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -2.28%
- EPS Growth Forecast
- 24.76%
Scores
- Smart Score
- 4
- AI Score
- 44

